CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
Atorvastatin 80mg +1 moredrug
Likely dose
Atorvastatin 80mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05567068
NCT05567068Phase 2Completed
CompareCT.gov

Repurposing Atorvastatin in Patients With Ulcerative Colitis Treated With Mesalamine by Modulation of mTOR/NLRP3 Pathway.

Tanta University·interventional·Posted Oct 5, 2022·Updated Nov 18, 2025

In Brief

A Phase 2 clinical trial evaluating Atorvastatin 80mg and Mesalamine for Inflammatory Bowel Diseases. Completed, enrolled 54 participants across 1 site.

Detailed Summary

Statins exert numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement, and immunomodulation independent of their basic lipid-lowering properties.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammatory Bowel Diseases
CountriesEgypt
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedOct 5, 2022
Enrollment StartFeb 1, 2023
Primary CompletionJun 1, 2025
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 3.7 years ago

Interventions

Atorvastatin 80mgdrug

Atrovastatin is one of the most effective drugs used to reduce intracellular cholesterol synthesis. it exerts numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement and immunomodulation independent of its basic lipid-lowering properties

Mesalaminedrug

Mesalamine